Matrix metalloproteinasesmolecular aspects of their roles in tumour invasion and metastasis

European Journal of Cancer

Volumn 36, Issue 13, 2000, Pages 1621-1630

  Curran, S ^a   Murray, G I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Gene regulation; Matrix metalloproteinase; Pathology; Tumour

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BATIMASTAT; BRYOSTATIN; CELL ADHESION MOLECULE; COLLAGENASE; CYCLIN D1; CYTOKINE; GELATINASE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; STROMELYSIN; TANOMASTAT; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE; CADHERIN; INTEGRIN; TUMOR PROTEIN;

CANCER INVASION; CELL ADHESION; DNA POLYMORPHISM; DRUG EFFECT; ENZYME ACTIVITY; GENE CONTROL; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION REGULATION; DRUG ANTAGONISM; GENETIC TRANSCRIPTION; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

CADHERINS; CELL ADHESION MOLECULES; HUMANS; INTEGRINS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; TRANSCRIPTION, GENETIC;

EID: 0033624445     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00156-8     Document Type: Article

References (69)

1. Llano E., Pendas A.M., Freije J.P.et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumours. Cancer Res. 59:1999;2570-2576.
2. Velasaco G., Pendas A.M., Feuyo A., Knauper V., Murphy G., Lopez-Otin C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 274:1999;4570-4576.
3. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 185:1998;256-261.
4. Sier C.F.M., Kubben F.J.G.M., Ganesh S.et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer. 74:1996;413-417.
5. Murray G.I., Duncan M.E., Arbuckle E., Melvin W.T. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut. 43:1998;791-797.
6. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. 2:1996;461-462.
7. Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 56:1996;190-196.
8. Ahmad A., Hanby A., Dublin E.et al. Stromelysin-3. an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression Am. J. Pathol. 152:1998;721-728.
9. Murashige M., Miyahara M., Shiraishi N., Saito T., Kohno K., Kobayashi M. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jap. J. Clin. Oncol. 26:1996;303-309.
10. Talvensaari-Mattila A., Paakko P., Hoyhtya M., Blanco-Sequeiros G., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein. a marker of aggressiveness in breast carcinoma Cancer. 83:1998;1153-1162.
11. Ree A.H., Florenes V.A., Berg J.P., Malandsmom G.M., Nesland J.M., Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 3:1997;1623-1628.
12. Fong K.M., Kida Y., Zimmerman P.V., Smith P.J. TIMP-1 and adverse prognosis in non-small cell lung cancer. Clin. Cancer Res. 2:1996;1369-1372.
13. Lijnen H.R., Ugwu F., Bini A., Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry. 37:1998;4699-4702.
14. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. 274:1999;29568-29571.
15. Patterson B.C., Sang A.Q. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272:1997;28823-28825.
16. Fowlkes J.L., Thrailkill K.M., Serra D.M., Suzuki K., Nagase H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog. Growth Factor Res. 6:1995;255-263.
17. Goss K.J., Brown P.D., Matrisian L.M. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int. J. Cancer. 78:1998;629-635.
18. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 189:1999;300-308.
19. Vincenti M.P., White L.A., Schroen D.J., Benbow U., Brinckerhoff C.E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase). mechanisms that control enzyme activity, transcription, and mRNA stability Crit. Rev. Eukaryot. Gene. Express. 6:1996;391-411.
20. Benbow U., Brinckerhoff C.E. The AP-1 site and MMP gene regulation. what is all the fuss about? Matrix Biol. 15:1997;519-526.
21. Crawford H.C., Matrisian L.M. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein. 49:1996;20-37.
22. Gutman A., Wasylyk B. Nuclear targets for transcription regulation by oncogenes. Trends Genet. 7:1991;49-54.
23. Bachman K.E., Herman J.G., Corn P.G.et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain and other human cancers. Cancer Res. 59:1999;798-802.
24. Rutter J.L., Mitchell T.I., Buttice G.A.et al. Single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 58:1998;5321-5325.
25. Kanamori Y., Matsushima M., Minaguchi T.et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 59:1999;4225-4227.
26. Bian J., Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol. 17:1997;6330-6338.
27. Sun Y., Wenger L., Rutter J.L., Brinckerhoff C.E., Cheung H.S. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J. Biol. Chem. 264:1999;11535-11540.
28. Schroen D.J., Brinckerhoff C.E. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Express. 6:1996;197-207.
29. Maquoi E., Noel A., Frankenne F., Angliker H., Murphy G., Foidart J.M. Inhibition of matrix metalloproteinase maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett. 424:1998;262-266.
30. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 375:1995;244-247.
31. Okumura Y., Sato H., Seiki M., Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett. 102:1997;181-184.
32. Chen W.T., Wang J.Y. Specialised surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann. NY Acad. Sci. 878:1999;361-371.
33. Hahn-Dantona E., Ramos-DeSimone N., Sipley J., Nagase H., French D.L., Quigley J.P. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Ann. NY Acad. Sci. 878:1999;372-387.
34. Nguyen M., Arkell J., Jackson C.J. Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of activated MTR1 matrix metalloproteinase. Lab. Invest. 79:1999;467-475.
35. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging Plasmin/Stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274:1999;13066-13076.
36. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science. 277:1997;225-228.
37. Brabletz T., Jung A., Dag S., Hlubek F., Kirchner T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 155:1999;1033-1038.
38. Clevers H., van de Wetering M. TCF/LEF factor earn their wings. Trend Genet. 13:1997;485-489.
39. Crawford H.C., Fingleton B.M., Rudolph-Owen L.A.et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumours. Oncogene. 18:1999;2883-2891.
40. Berx G., Nollet F., van Roy F. Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. Cell. Adhes. Commun. 6:1998;171-184.
41. Cheresh D.A. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metast. Rev. 10:1991;3-10.
42. Brooks P.C., Stromblad S., Sanders L.C.et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 85:1996;683-693.
43. Jones J.L., Walker R.A. Control of matrix metalloproteinase activity in cancer. J. Pathol. 183:1997;377-379.
44. Maecker H.T., Todd S.C., Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 11:1997;428-442.
45. Berditchevski F., Odintsova E. Characterization of integrin-tetraspanin adhesion complexes. role of tetraspanins in integrin signalling J. Cell. Biol. 146:1999;477-492.
46. Sugiura T., Berditchevski F. Function of alpha3beta1-tetraspanin protein complexes in tumour cell invasion. Evidence for the role of complexes in production of metalloproteinase 2 (MMP-2). J. Cell. Biol. 146:1999;1375-1389.
47. Niu J., Gu X., Turton J., Meldrum C., Howard E.W., Agrez M. Integrin-mediated signalling of gelatinase B secretion in colon cancer cells. Biochem. Biophys. Res. Commun. 249:1998;287-291.
48. Agrez M., Gu X., Turton J.et al. The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. Int. J. Cancer. 81:1999;90-97.
49. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13:1999;35-48.
50. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14:2000;163-176.
51. Borghaei R.C., Rawlings P.L. Jr., Mochan E. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum. 41:1998;1398-1406.
52. Kossakowska A.E., Edwards D.R., Prusinkiewicz C.et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood. 94:1999;2080-2089.
53. Stearns M.E., Rhim J., Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis. IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion Clin. Cancer Res. 5:1999;189-196.
54. Bar-Eli M. Role of interleukin-8 in tumour growth and metastasis of human melanoma. Pathobiology. 67:1999;12-18.
55. Macaulay V.M., O'Byrne K.J., Saunders M.P.et al. Phase I study of intrapleural Batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 5:1999;513-520.
56. Wylei S., MacDonald I.C., Varghese H.J.et al. The matrix metalloproteinase inhibitor Batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin. Exp. Metast. 17:1999;111-117.
57. Tierney G.M., Griffin N.R., Stuart R.C.et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor Marimastat in gastric cancer. Eur. J. Cancer. 35:1999;563-568.
58. Jones L., Ghaneh P., Humphreys M., Neoptolemos J.P. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann. NY Acad. Sci. 880:1999;288-307.
59. Koivunen E., Arap W., Valtanen H.et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol. 17:1999;768-774.
60. Gatto C., Rieppi M., Borsotti P.et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin. Cancer Res. 5:1999;3603-3607.
61. Price A., Shi Q., Morris D.et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5:1999;845-854.
62. Trachtman H., Futterweit S., Greenwald R.et al. Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 229:1996;243-248.
63. Lokeshwar B.L. MMP inhibition in prostate cancer. Ann. NY Acad. Sci. 878:1999;271-289.
64. An Z., Wang X., Willmott N.et al. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin. Exp. Metast. 15:1997;184-195.
65. Watson S.A., Morris T.M., Collins H.M., Bawden L.J., Hawkins K., Bone E.A. Inhibition of tumour growth by Marimastat in a human xenografts model of gastric cancer. relationship with levels of circulating CEA Br. J. Cancer. 81:1999;19-23.
66. Tanaka H., Nishida K., Sugita K., Yoshioka T. Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor. Jpn. J. Cancer Res. 90:1999;1139-1145.
67. Miyazaki K., Koshikawa N., Hasegawa S.et al. Matrilysin as a target for chemotherapy for colon cancer. use of antisense oligonucleotides as antimetastatic agents Cancer Chemother. Pharmacol. 43S:1999;S52-S55.
68. Hua J., Muschel R.J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56:1996;5279-5284.
69. Peng K.W., Morley F.J., Cosset F.L., Murphy G., Russel S.J. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum. Gene. Ther. 8:1997;729-738.